Dennis McBride - NRX Pharmaceuticals Chief Scientist
| NRXP Stock | USD 1.27 0.04 3.05% |
Insider
Dennis McBride is Chief Scientist of NRX Pharmaceuticals
| Address | 1201 Orange Street, Wilmington, DE, United States, 19801 |
| Phone | (484) 254-6134 |
| Web | https://www.nrxpharma.com |
NRX Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (1.1597) % which means that it has lost $1.1597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.8261) %, meaning that it created substantial loss on money invested by shareholders. NRX Pharmaceuticals' management efficiency ratios could be used to measure how well NRX Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NRX Pharmaceuticals' Return On Capital Employed is relatively stable compared to the past year. As of 11/26/2024, Return On Equity is likely to grow to 2.70, though Return On Tangible Assets are likely to grow to (3.92). Change To Liabilities is expected to grow at the current pace this year, while Total Current Liabilities is likely to drop slightly above 14.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Susan Kahlert | Senti Biosciences | N/A | |
| Philip Ainslie | Lexaria Bioscience Corp | N/A | |
| Amro Albanna | Aditxt Inc | 54 | |
| MD FACC | Longeveron LLC | 61 | |
| Jonathan MBA | Biomx Inc | 47 | |
| James Ahlers | RenovoRx | 60 | |
| KwanHong MD | Longeveron LLC | 57 | |
| Jeffrey PharmD | Nutriband | 54 | |
| Rowena Albanna | Aditxt Inc | 58 | |
| Inbar GahaliSass | Biomx Inc | N/A | |
| Vanessa Carle | Lexaria Bioscience Corp | N/A | |
| Angela Nelms | RenovoRx | 47 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Craig Esq | Cingulate | 51 | |
| Gerald Goodman | Nutriband | 76 | |
| Ronald CPA | RenovoRx | N/A | |
| Merav Bassan | Biomx Inc | 58 | |
| Eran MD | Biomx Inc | N/A | |
| CPA CMA | Lexaria Bioscience Corp | 63 | |
| Deborah Knobelman | Senti Biosciences | 50 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
Management Performance
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 |
NRX Pharmaceuticals Leadership Team
Elected by the shareholders, the NRX Pharmaceuticals' board of directors comprises two types of representatives: NRX Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NRX. The board's role is to monitor NRX Pharmaceuticals' management team and ensure that shareholders' interests are well served. NRX Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NRX Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Suzanne Messere, Investor Relations | ||
| Robert MIM, Chief Operations | ||
| Michael Kunz, Gen Sec | ||
| Stephen Esq, CEO Secretary | ||
| Richard Narido, Principal CFO | ||
| Molly Cogan, Sr Affairs | ||
| Seth Voorhees, CFO Treasurer | ||
| Dennis McBride, Chief Scientist | ||
| Matthew Duffy, Chief Therapeutics | ||
| Prof Javitt, CoFounder Board | ||
| Riccardo Panicucci, Chief Officer | ||
| MPH MD, Chief CoFounder | ||
| Philip Lavin, Chief Methodologist |
NRX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NRX Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| Current Valuation | 20.87 M | ||||
| Shares Outstanding | 12.09 M | ||||
| Shares Owned By Insiders | 23.56 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 682.66 K | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) |
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with NRX Stock
Moving against NRX Stock
| 0.71 | KZR | Kezar Life Sciences | PairCorr |
| 0.62 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.36 | NXGLW | NexGel Warrant | PairCorr |
| 0.32 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.